Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Published in: Neurotherapeutics 1/2006

01-01-2006

Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder

Authors: Christopher Pittenger, John H. Krystal, Vladimir Coric

Published in: Neurotherapeutics | Issue 1/2006

Login to get access
Metadata
Title
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder
Authors
Christopher Pittenger
John H. Krystal
Vladimir Coric
Publication date
01-01-2006
Publisher
Springer-Verlag
Published in
Neurotherapeutics / Issue 1/2006
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1016/j.nurx.2005.12.006

Other articles of this Issue 1/2006

Neurotherapeutics 1/2006 Go to the issue

OriginalPaper

Neural circuitry and neuroplasticity in mood disorders: Insights for novel therapeutic targets

OriginalPaper

Advances in the treatment of anxiety: Targeting glutamate

OriginalPaper

Imaging genomics and response to treatment with antipsychotics in schizophrenia

OriginalPaper

Pharmacogenetic tools for the development of target-oriented cognitive-enhancing drugs

OriginalPaper

Catechol-O-methyltransferase polymorphisms and some implications for cognitive therapeutics

Editorial

New directions in psychiatric therapeutics